CLINICAL AND GENETIC FEATURES OF THE COURSE OF TYPE 2 DIABETES MELLITUS IN THE BACKGROUND OF CARDIOVASCULAR DISEASES AFTER COVID-19
Main Article Content
Abstract
During the COVID-19 pandemic, many prominent studies have confirmed a direct relationship between the severity of infectious disease and a history of diabetes mellitus. A meta-analysis of 8 studies involving almost 50 thousand patients with COVID-19 showed that diabetes mellitus (DM) ranks second among the most common comorbidities after coronary artery disease and arterial hypertension. In the pathogenesis of the development of DM, there are metabolic, hemodynamic, hemostasis, and genetic changes [2].
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Angelidi A.M., Belanger M.J., Mantzoros C.S. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metabolism 2020; 107: 154245, https://doi.org/10.1016/j
Abou-Ismail M.Y., Diamond A., Kapoor S., Arafah Y., Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res 2020; 194: 101–115, https://doi.org/10.1016/j.thromres.2020.06.029. 3. Center for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). U.S. Department of Health & Human Services; 2020. URL: https://www.cdc.gov/ coronavirus/2019-ncov/hcp/clinical-guidance-managementpatients.html.